MYC and prostate cancer: When the androgen-sensitive LNCaP prostate cancer cells are chronically treated with enzalutamide to make resistant cells (LNCaP-ENR), they show overexpression of c-Myc both at the mRNA as well as protein levels (Fig. 1A–D).